Literature DB >> 23784927

Treatment of extended-spectrum Beta-lactamase enterobacteriaceae with cefepime: the dose matters, too.

Jerry Altshuler, Samuel L Aitken, David Guervil, Diana Esaian, John Papadopoulos, Cesar A Arias.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23784927      PMCID： PMC4014853          DOI： 10.1093/cid/cit383

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  5 in total

1.  Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.

Authors:  Juliana F Roos; Jurgen Bulitta; Jeffrey Lipman; Carl M J Kirkpatrick
Journal:  J Antimicrob Chemother       Date:  2006-08-30       Impact factor: 5.790

Review 2.  Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.

Authors:  D Andes; W A Craig
Journal:  Clin Microbiol Infect       Date:  2005-11       Impact factor: 8.067

3.  Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.

Authors:  Nan-Yao Lee; Ching-Chi Lee; Wei-Han Huang; Ko-Chung Tsui; Po-Ren Hsueh; Wen-Chien Ko
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

Review 4.  Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

Authors:  Michael N Dudley; Paul G Ambrose; Sujata M Bhavnani; William A Craig; Mary Jane Ferraro; Ronald N Jones
Journal:  Clin Infect Dis       Date:  2013-01-18       Impact factor: 9.079

5.  Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by gram-negative organisms.

Authors:  Sunil V Bhat; Anton Y Peleg; Thomas P Lodise; Kathleen A Shutt; Blair Capitano; Brian A Potoski; David L Paterson
Journal:  Antimicrob Agents Chemother       Date:  2007-10-15       Impact factor: 5.191
  5 in total
  2 in total

Review 1.  Updates in the Management of Cephalosporin-Resistant Gram-Negative Bacteria.

Authors:  Andre Arizpe; Kelly R Reveles; Shrina D Patel; Samuel L Aitken
Journal:  Curr Infect Dis Rep       Date:  2016-12       Impact factor: 3.725

Review 2.  Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae.

Authors:  Allison M Gibble; Alan E Gross; Angela M Huang
Journal:  Antibiotics (Basel)       Date:  2015-12-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.